Affiliation:
1. Department of Emergency Medicine, People’s Hospital of Dongxihu District , Wuhan , Hubei, 430040 , China
2. Department of Neurology, People’s Hospital of Dongxihu District , 48 Jinbei 1st Road, Jinghe Street, Dongxihu District , Wuhan , Hubei, 430040 , China
3. Department of Emergency Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine , Wuhan , China
Abstract
Abstract
Objective
In this prospective observational study, we aimed to investigate the serum levels of sirtuin (SIRT)3 in epilepsy patients and its association with the severity of the disease.
Methods
This prospective observational study included 203 patients with symptomatic epilepsy and 100 healthy controls who visited our hospital from November 2019 to November 2022. The severity of the disease in epilepsy patients was assessed using the National Hospital Seizure Severity Scale (NHS3). We used enzyme-linked immunosorbent assay to measure the serum levels of SIRT3, interleukin (IL)-6, IL-1β, tumor necrosis factor-alpha, and C-reactive protein in all patients. In addition, the cognitive function of all study participants was evaluated using the Mini-Mental State Examination and the Montreal Cognitive Assessment (MOCA). All data were analyzed using SPSS 25.0 software.
Results
The MOCA scores of the epilepsy patients were significantly lower compared to the healthy volunteers (P < 0.05). The serum SIRT3 levels were decreased significantly in patients with refractory epilepsy (183.16 ± 17.22 pg/mL) compared to non-refractory epilepsy patients (199.00 ± 18.68 pg/mL). In addition, serum SIRT3 levels were negatively correlated with the inflammatory factors IL-6 (Pearson’s correlation −0.221, P = 0.002) and NHS score (Pearson’s correlation −0.272, P < 0.001) of epilepsy patients, while positively correlated with MOCA scores (Pearson’s correlation 0.166, P = 0.018). Furthermore, the receiver operating characteristic curve demonstrated that serum SIRT3 could be used to diagnose epilepsy, as well as refractory epilepsy. Finally, logistic regression analysis showed that SIRT3 (OR = 1.028, 95%CI: 1.003–1.054, P = 0.028), IL-6 (OR = 0.666, 95%CI: 0.554–0.800, P < 0.001), IL-1β (OR = 0.750, 95%CI: 0.630–0.894, P = 0.001), and NHS3 (OR = 0.555, 95%CI: 0.435–0.706, P < 0.001) were risk factors for refractory epilepsy.
Conclusion
In conclusion, our findings demonstrated that serum SIRT3 levels were significantly decreased in epilepsy patients and further decreased in patients with refractory epilepsy. This study might provide new therapeutic targets and comprehensive treatment strategies for epilepsy patients.
Reference41 articles.
1. Singh A, Trevick S. The epidemiology of global epilepsy. Neurol Clin. 2016;34(4):837–47. 10.1016/j.ncl.2016.06.015.
2. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–21.
3. Kobylarek D, Iwanowski P, Lewandowska Z, Limphaibool N, Szafranek S, Labrzycka A, et al. Advances in the potential biomarkers of epilepsy. Front Neurol. 2019;10:685.
4. Vasileva Z. Melatonin and epilepsy. Folia Med. 2021;63(6):827–33.
5. Rocha AKA, Cipolla-Neto J, Amado D. Epilepsy: neuroprotective, anti-inflammatory, and anticonvulsant effects of melatonin. Melatonin: medical uses and role in health and disease. New York: Nova Science Publishers; 2018.